Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016
The Spectrum of Statin Myopathy
Curr Opin Rheumatol 25:747-752, Mohassel, P. & Mammen, A.L., 2013
Statin Use During Ischemic Stroke Hospitalization is Strongly Associated with Improved Poststroke Survival
Stroke 43:147-154, Flint, A.C.,et al, 2012
Statin Therapy After First Stroke Reduces 10-Year Stroke Recurrence and Improves Survival
Neurol 72:1816-1822, Milionis,H.J.,et al, 2009
Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
Stroke 40:3526-3531,3413, Goldstein,L.,et al, 2009
Discontinuation of Statin Therapy and Clinical and Outcome After Ischemic Stroke
Stroke 38:2652-2657, Colvicchi,F.,et al, 2007
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Antiplatelets, ACE Inhibitors, and Statins Combination Reduces Stroke Severity and Tissue At Risk
Neurol 66:1153-1158, Kumar,S.,et al, 2006
HMG-CoA Reductase Inhibitors Improve Acute Ischemic Stroke Outcomes
Stroke 36:1298-1300, Moonis,M.,et al, 2005
Lipid-Lowering Agent Use at Ischemic Stroke Onset is Associated with Decreased Mortality
Neurol 65:253-258, Elkind,M.S.V.,et al, 2005
Rhabdomyolysis: An Evaluation of 475 Hospitalized Patients
Medicine 84:377-385, Melli,G.,et al, 2005
Favorable Outcome of Ischemic Stroke in Patients Pretreated with Statins
Stroke 35:1117-1123, Marti-Fabregas,J.,et al, 2004
Statin-Associated Myopathy
JAMA 289:1681-1690, Thompson,P.D.,et al, 2003
Influence of Cholesterol on Survival After Stroke:Retrospective Study
BMJ 314:1584-1588, Dyker,A.G.,et al, 1997
Cholesterol-Lowering Agent Myopathy (CLAM)
Neurol 41:1159-1160, London,S.F.,et al, 1991
Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024
Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Patients with Melanoma
Neurol 101:e2472-e2482, Pepys,J.,et al, 2023
Idiopathic Intracranial Hypertension (Pseudotumor Cerebri): Prognosis and Treatment
www.UptoDate.com Mar, Wall, M. & Lee, A.G., 2022
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Cerebral Venous Thrombosis
NEJM 385:59-64, Ropper, A.H. & Kline, J.P., 2021
Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021
Clinical Outcomes in Atrial Fibrillation Patients with a History of Cancer Treated with Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 52:3132-3141, Chan, Y.H.,et al, 2021
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Association of Innovations in Radiotherapy and Systemic Treatments with Clinical Outcomes in Patients with Melanoma Brain Metastasis From 2007 to 2016
JAMA doi:10.1001/JAMANETWORKOPEN.2020.8204, Brastianos, H.C.,et al, 2020
Clinical Effectiveness of Direct Oral Anticoagulations vs Warfarin in Older Patients with Atrial Fibrillation and Ischemic Stroke
JAMA Neurol 76:1192-1202, Xian, Y.,et al, 2019
Persistent Postural-Perceptual Dizziness (PPPD): A Common, Characteristic and Treatable Cause of Chronic Dizziness
Pract Neurol 18:5-13, Popkirov, S.,et al, 2018
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Outcome of Intracerebral Hemorrhage Associated with Different Oral Anticoagulants
Neurol 88:1693-1700,1686, Wilson, D.,et al, 2017
Infliximab for the Treatment of CNS Sarcoidosis
Neurol 89:2092-2100, Gelfand, J.M.,et al, 2017
Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants
JAMA Neurol 73:169-177,155, Purrucker, J.C.,et al, 2016
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
CBRNE - Nerve Agents, V-series - Ve, Vg, Vm, Vx
emedicine Feb, Keyes, D.C. & Caneva, D.C., 2015
Bevacizumab in Glioblastoma - Still Much to Learn
NEJM 370:764-765, Fine, H.A., 2014
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
Intracraial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation with Warfarin or Dabigatran
Stroke 43:1511-1517, Hart, R.G.,et al, 2012
Selective Serotonin Reuptake Inhibitors May be Helpful in Most Patients with Stroke
Stroke 43:3150-3151,3154, Chollet, F., 2012
Should Every Patient with Stroke be on Selective Serotonin Reuptake Inhibitors?
Stroke 43:3152-3153,3154, Marshall, R.S., 2012
Dropped Head Syndrome: Report of Three Cases During Treatment with a Mek Inhibitor
Neurol 79:1929-1932, Chen, X.,et al, 2012
PML-IRIS in a patient treated with Brentuximab
Neurol 79:2075-2077, Geldern, G.,et al, 2012
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Neurosacrcoidosis: Presentations and Management
Neurologist 16:2-15, Terushkin,V.,et al, 2010
Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010
A Case of Neurosarcoidosis Successfully Treated with Rituximab
Neurol 75:568-570, Bomprezzi,R., et al, 2010